Market Cap | 312.38M | P/E | - | EPS this Y | -0.50% | Ern Qtrly Grth | - |
Income | -56.07M | Forward P/E | -5.21 | EPS next Y | 13.20% | 50D Avg Chg | 12.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 33.00% |
Dividend | N/A | Price/Book | 2.89 | EPS next 5Y | - | 52W High Chg | -34.00% |
Recommedations | 2.10 | Quick Ratio | 8.81 | Shares Outstanding | 29.65M | 52W Low Chg | 189.00% |
Insider Own | 29.17% | ROA | -37.42% | Shares Float | 19.11M | Beta | -0.61 |
Inst Own | 32.51% | ROE | -61.81% | Shares Shorted/Prior | 3.02M/1.98M | Price | 10.68 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 118,643 | Target Price | 11.21 |
Oper. Margin | - | Earnings Date | - | Volume | 52,517 | Change | 0.38% |
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Needham | Buy | Sep 13, 24 |
Chardan Capital | Buy | Aug 7, 24 |
Needham | Buy | Aug 7, 24 |
Needham | Buy | May 8, 24 |
Needham | Buy | Apr 12, 24 |
Mizuho | Buy | Apr 2, 24 |
Jefferies | Hold | Mar 15, 24 |
Chardan Capital | Buy | Mar 15, 24 |
Needham | Buy | Mar 15, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Zeskind Benjamin J. | PRESIDENT AND CEO PRESIDENT AND CEO | Dec 22 | Option | 3.01 | 2,500 | 7,525 | 2,261,852 | 12/27/22 |
Bookman Michael | GENERAL COUNSEL AND.. GENERAL COUNSEL AND SECRETARY | May 17 | Buy | 4.88 | 1,000 | 4,880 | 2,402 | 05/18/22 |
KEATING LAURIE | Director Director | May 16 | Buy | 5 | 7,000 | 35,000 | 14,000 | 05/17/22 |
Amin Biren | CFO, TREASURER CFO, TREASURER | May 12 | Buy | 4.42 | 1,000 | 4,420 | 7,898 | 05/12/22 |
Zeskind Benjamin J. | PRESIDENT AND CEO PRESIDENT AND CEO | Apr 12 | Option | 3.01 | 2,000 | 6,020 | 2,259,352 | 04/14/22 |
Zeskind Benjamin J. | PRESIDENT AND CEO PRESIDENT AND CEO | Mar 23 | Buy | 8.02 | 3,000 | 24,060 | 2,257,352 | 03/24/22 |
Hall Brett Matthew | CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER | Mar 23 | Buy | 7.91 | 1,050 | 8,306 | 330,134 | 03/23/22 |
Barrett Scott | CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER | Mar 22 | Buy | 7.485 | 900 | 6,736 | 7,563 | 03/22/22 |
Feinberg Peter | Director Director | Mar 15 | Buy | 6.75 | 6,667 | 45,002 | 11,766 | 03/16/22 |
BERMAN ANN E | Director Director | Mar 15 | Buy | 6.40 | 6,000 | 38,400 | 9,500 | 03/15/22 |
Zeskind Benjamin J. | PRESIDENT AND CEO PRESIDENT AND CEO | Feb 28 | Option | 3.01 | 2,000 | 6,020 | 2,254,352 | 03/01/22 |